Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 07.10.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | corporated by reference in this Item 5.01. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 09.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 01.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Unternehmen & Branche
| Name | Verona Pharma plc |
|---|---|
| Ticker | VRNA |
| CIK | 0001657312 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 72,68 Mrd. USD |
| Beta | 0,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-06-30 | 10-Q | 103,138,000 | 11,921,000 | 0.02 | 572,871,000 | 278,273,000 |
| 2025-03-31 | 10-Q | 76,256,000 | -16,319,000 | -0.02 | 525,936,000 | 226,595,000 |
| 2024-12-31 | 10-K | 42,279,000 | -173,418,000 | -0.27 | 474,242,000 | 204,559,000 |
| 2024-09-30 | 10-Q | 5,624,000 | -42,962,000 | -0.07 | 381,818,000 | 130,491,000 |
| 2024-06-30 | 10-Q | 0 | -70,835,000 | -0.11 | 434,123,000 | 168,274,000 |
| 2024-03-31 | 10-Q | 0 | -25,794,000 | -0.04 | 289,912,000 | 224,988,000 |
| 2023-12-31 | 10-K | 0 | -54,369,000 | -0.09 | 308,124,000 | 249,283,000 |
| 2023-09-30 | 10-Q | 0 | -14,687,000 | -0.02 | 292,470,000 | 263,533,000 |
| 2023-06-30 | 10-Q | -8,807,000 | -0.01 | 303,929,000 | 273,093,000 | |
| 2023-03-31 | 10-Q | -16,743,000 | -0.03 | 323,146,000 | 276,749,000 | |
| 2022-12-31 | 10-K | 458,000 | -68,701,000 | -0.13 | 259,468,000 | 230,466,000 |
| 2022-09-30 | 10-Q | 0 | -15,647,000 | -0.03 | 274,872,000 | 237,485,000 |
| 2022-06-30 | 10-Q | -17,766,000 | -0.04 | 154,856,000 | 110,880,000 | |
| 2022-03-31 | 10-Q | -24,837,000 | -0.05 | 169,315,000 | 126,307,000 | |
| 2021-12-31 | 10-K | 40,000,000 | -55,569,000 | -0.12 | 186,587,000 | 148,005,000 |
| 2021-09-30 | 10-Q | 40,000,000 | 11,051,000 | 0.02 | 201,560,000 | 168,202,000 |
| 2021-06-30 | 10-Q | -22,068,000 | -0.05 | 218,502,000 | 154,397,000 | |
| 2021-03-31 | 10-Q | -21,290,000 | -0.05 | 190,150,000 | 172,414,000 | |
| 2020-12-31 | 10-K | 0 | -65,146,000 | 204,206,000 | 184,854,000 | |
| 2020-09-30 | 10-Q | 0 | -18,931,000 | -0.05 | 196,762,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-01 | Edwards Martin | Director | Open Market Sale | -10,808 | 13.14 | -142,057.11 | -12,3% | |
| 2025-08-01 | Rickard Kathleen A. | Officer, Chief Medical Officer | Open Market Sale | -58,336 | 13.14 | -766,750.88 | -66,5% | |
| 2025-08-01 | EBSWORTH DAVID R | Director | Open Market Sale | -1,904 | 13.14 | -25,025.60 | -2,2% | |
| 2025-08-01 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -208,912 | 13.14 | -2,745,876.65 | -238,0% | |
| 2025-08-01 | Brady James Aloysius | Director | Open Market Sale | -824 | 13.14 | -10,830.41 | -0,9% | |
| 2025-08-01 | Deschamps Lisa | Director | Open Market Sale | -9,464 | 13.14 | -124,391.98 | -10,8% | |
| 2025-08-01 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -208,912 | 13.14 | -2,745,876.65 | -238,0% | |
| 2025-08-01 | Fisher Andrew | Officer, General Counsel | Open Market Sale | -9,584 | 13.14 | -125,969.22 | -10,9% | |
| 2025-08-01 | Cunningham Kenneth | Director | Open Market Sale | -10,808 | 13.14 | -142,057.11 | -12,3% | |
| 2025-08-01 | Sinha Vikas | Director | Open Market Sale | -4,328 | 13.14 | -56,885.93 | -4,9% | |
| 2025-08-01 | SHAH MAHENDRA | Director | Open Market Sale | -3,608 | 13.14 | -47,422.47 | -4,1% | |
| 2025-08-01 | Austwick Michael | Director | Open Market Sale | -11,288 | 13.14 | -148,366.09 | -12,9% | |
| 2025-08-01 | ACKERMANN CHRISTINA | Director | Open Market Sale | -1,808 | 13.14 | -23,763.81 | -2,1% | |
| 2025-06-16 | Fisher Andrew | Officer, General Counsel | Open Market Sale | -80,000 | 11.53 | -922,000.00 | -79,9% | |
| 2025-06-11 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -400,000 | 11.40 | -4,560,360.00 | -395,3% | |
| 2025-06-11 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -400,000 | 11.40 | -4,560,520.00 | -395,4% | |
| 2025-05-29 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -208,696 | 9.33 | -1,947,592.81 | -168,8% | |
| 2025-05-29 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -204,864 | 9.33 | -1,911,667.93 | -165,7% | |
| 2025-05-28 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -162,704 | 9.30 | -1,513,293.63 | -131,2% | |
| 2025-05-28 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -157,704 | 9.30 | -1,466,804.90 | -127,2% | |
| 2025-05-27 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -33,600 | 9.53 | -320,181.12 | -27,8% | |
| 2025-05-27 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -32,432 | 9.53 | -308,982.91 | -26,8% | |
| 2025-05-20 | Sinha Vikas | Director | Open Market Sale | -160,000 | 9.39 | -1,502,928.00 | -130,3% | |
| 2025-05-15 | Fisher Andrew | Officer, General Counsel | Open Market Sale | -80,000 | 8.57 | -685,600.00 | -59,4% | |
| 2025-05-14 | ACKERMANN CHRISTINA | Director | Open Market Sale | -40,000 | 8.44 | -337,600.00 | -29,3% | |
| 2025-05-06 | Rickard Kathleen A. | Officer, Chief Medical Officer | Open Market Sale | -114,984 | 8.82 | -1,014,342.85 | -87,9% | |
| 2025-05-02 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -400,000 | 9.09 | -3,637,720.00 | -315,4% | |
| 2025-05-02 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -400,000 | 9.09 | -3,637,520.00 | -315,3% | |
| 2025-05-01 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -108,272 | 8.95 | -969,056.05 | -84,0% | |
| 2025-05-01 | Rickard Kathleen A. | Officer, Chief Medical Officer | Open Market Sale | -27,336 | 8.95 | -244,662.67 | -21,2% | |
| 2025-05-01 | Rickard Kathleen A. | Officer, Chief Medical Officer | Open Market Sale | -21,864 | 8.95 | -195,687.17 | -17,0% | |
| 2025-05-01 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -108,272 | 8.95 | -969,056.05 | -84,0% | |
| 2025-05-01 | ZACCARDELLI DAVID | Director, Officer, President and CEO | Open Market Sale | -78,736 | 8.95 | -704,702.95 | -61,1% | |
| 2025-05-01 | Hahn Mark W | Officer, Chief Financial Officer | Open Market Sale | -78,736 | 8.95 | -704,702.95 | -61,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.